Clinical characteristics and prognosis of AIDS related lymphoma: An analysis of 84 cases
10.3760/cma.j.issn.1674-2397.2022.06.003
- VernacularTitle:艾滋病相关淋巴瘤84例临床特征和预后分析
- Author:
Jiangjin HUI
1
;
Zhikai WAN
;
Guanjing LANG
;
Bohao DAI
;
Biao ZHU
Author Information
1. 浙江大学医学院附属第一医院感染病科 传染病诊治国家重点实验室 感染性疾病诊治协同创新中心 国家感染性疾病临床医学研究中心，杭州 310003
- Keywords:
Acquired immunodeficiency syndrome;
Lymphoma;
Clinical characteristics;
Prognosis
- From:
Chinese Journal of Clinical Infectious Diseases
2022;15(6):448-453
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical characteristics and prognosis of patients with AIDS-related lymphoma (ARL).Methods:The clinical data of 84 patients with ARL admitted in the First Affiliated Hospital Zhejiang University School of Medicine from March 2013 to October 2021 were retrospectively reviewed, and the influencing factors for prognosis of patients were analyzed by Cox proportional risk regression model.Results:Non-Hodgkin’s lymphoma accounted for 95.2% (80/84) of all cases; 52.3% (44/84) of the patients presented with B symptoms of lymphoma such as fever, night sweats, and weight loss, and 84.5% (71/84) of them were classified as stage Ⅲ~Ⅳ by Ann Arbor staging; 58.0% (47/81) patients had CD4 + T cell count ≤200/μL at baseline; 30 (35.7%) patients had pulmonary infection, 11 (13.1%) patients had digestive tract infection, and 21.4% (18/84) patients had sepsis. The 1-year survival rate of 84 patients was 70.2% (59/84). Multivariate Cox survival analysis showed that International prognostic index (IPI) score >3 ( HR=5.094, 95% CI 1.877-13.824, P=0.001) was an independent risk factors and rituximab treatment ( HR=0.354, 95% CI 0.152-0.823, P=0.016) was an independent protective factor for the prognosis of patients with ARL. Conclusions:The clinical manifestations of ARL are diverse, and it is often diagnosed in the late stage of the disease with adverse prognosis. IPI score and Rituximab treatment are key prognostic factors in patients with ARL.
